Comparative Pharmacology
Head-to-head clinical analysis: COLISTIMETHATE SODIUM versus POLYMYXIN B SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLISTIMETHATE SODIUM versus POLYMYXIN B SULFATE.
COLISTIMETHATE SODIUM vs POLYMYXIN B SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colistimethate sodium is a prodrug that hydrolyzes to colistin, a polymyxin antibiotic. Colistin disrupts bacterial cell membrane integrity by binding to lipopolysaccharides and phospholipids, increasing permeability leading to cell death.
Polymyxin B sulfate binds to lipopolysaccharides (LPS) in the outer membrane of gram-negative bacteria, disrupting membrane integrity and causing cell death. It also has anti-endotoxin activity.
2.5-5 mg/kg/day IV divided every 8-12 hours, based on colistin base activity (CBA). The typical dose is 2.5-5 mg/kg/day of colistimethate sodium (CMS) administered intravenously in 2-3 divided doses. For critically ill patients, a loading dose of 5 mg/kg CBA (approximately 9 million IU) may be given, followed by maintenance doses adjusted for renal function.
1.5 to 2.5 mg/kg/day IV divided every 12 hours; maximum 2.5 mg/kg/day. For topical use, apply 0.1% to 0.25% (10,000 to 25,000 units/g) ointment or cream 1-4 times daily.
None Documented
None Documented
In adults with normal renal function: 2-3 hours (terminal). Prolonged to 20-40 hours in moderate-severe renal impairment; >40 hours in anuria. Dose adjustment required for CrCl <50 mL/min.
Terminal elimination half-life is approximately 7-10 hours in adults with normal renal function. In patients with severe renal impairment (CrCl <30 mL/min), half-life may be prolonged to 2-3 days. Half-life is significantly extended in anuria (up to 48-72 hours). Clinically, dosing must be adjusted based on renal function and therapeutic drug monitoring is recommended.
Primarily renal (tubular secretion and glomerular filtration); 60-70% of the dose is excreted unchanged in urine within 24 hours, with up to 80% recovered over 48 hours. Minor biliary/fecal elimination (<4%).
Primarily renal excretion of unchanged drug via glomerular filtration (approx. 60-70% of a dose is recovered in urine as active polymyxin B). A smaller fraction (approximately 10-20%) is eliminated via non-renal pathways (biliary/fecal) as unchanged drug and minor metabolites; biliary excretion accounts for <5%.
Category C
Category C
Polymyxin Antibiotic
Polymyxin Antibiotic